<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829957</url>
  </required_header>
  <id_info>
    <org_study_id>RAMBLE</org_study_id>
    <nct_id>NCT02829957</nct_id>
    <nct_alias>NCT02761044</nct_alias>
  </id_info>
  <brief_title>RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding</brief_title>
  <acronym>RAMBLE</acronym>
  <official_title>Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large proportion of women with menstruating potential with newly diagnosed VTE or atrial
      fibrillation, treated with apixaban will have less menstrual blood loss than patients
      randomized to rivaroxaban.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PBAC scores</measure>
    <time_frame>3 months</time_frame>
    <description>&lt; 100 normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of discontinuation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that held drug for menorrhagia</measure>
    <time_frame>1, 2, and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of major hemorrhage</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of recurrent VTE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of crossover to another anticoagulant</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically relevant non-major bleeding</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical component summary of standard from 36</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Menstruation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>10mg BID for 7 days, then 5mg BID for three months</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>15mg BID for 7 days, then 20mg daily for three months</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant women, age 18-50,

          -  Objectively diagnosed VTE or atrial fibrillation within the previous 30 days, and no
             menstrual cycle since diagnosis

          -  Patient reported active menstruation, requiring &gt;3 menstrual periods in the previous 6
             months

          -  Clinical plan and patient agreement to treat with oral anticoagulation for 3 months or
             longer

          -  Patients must have a working mobile phone

        Exclusion Criteria:

          -  Package insert exclusions for Eliquis (Apixaban) or Xarelto (Rivaroxaban): [active
             pathological bleeding or severe hypersensitivity reaction to XARELTO or ELIQUIS (e.g.,
             anaphylactic reactions)]

          -  Plan to become pregnant in the next three months.

          -  Concomitant prescribed use of aspirin or thienopyridine or other platelet inhibiting
             drugs

          -  Plan for surgical hysterectomy or endometrial ablation

          -  Known uterine cancer

          -  Von Willebrand's disease, or hemophilia

          -  Known coagulopathy from liver disease

          -  Conditions likely to preclude adherence to study procedures: Active intravenous drug
             use, known alcoholism, homelessness, or uncontrolled psychiatric illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cassandra Hall</last_name>
    <phone>317-962-1190</phone>
    <email>clsh@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Pettit</last_name>
    <phone>317-962-1190</phone>
    <email>klpettit@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eskenazi Health System</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

